UPDATE: Click here to order samples for your practice.


Choose selective VEGF therapy with proven long-term efficacy

Selective anti-VEGF mode of action*
Targets major pathological VEGF isoform (VEGF165

MACUGEN® is a proven, effective option

for long-term maintenance therapy in wet AMD for up to 2 years²

Visual acuity remained stable with long-term (up to 2 years) therapy with MACUGEN®²

Mean visual acuity from Week 54 to Week 102²

MACUGEN® has an established safety profile

In the MACUGEN® pivotal study, a 2-year safety profile was demonstrated with³:

No evidence of VEGF inhibitor-mediated toxicity to the retinal or choroidal vasculature

Serious adverse events related to the injection procedure occurred in <1% of intravitreous injections included¹:

  • Endophthalmitis
  • Retinal detachment
  • Iatrogenic traumatic cataract
  • Please see Important Safety Information below
How to order MACUGEN® for your patients


MACUGEN® (pegaptanib sodium injection) is indicated for the treatment of neovascular (wet) age-related macular degeneration.

Important Safety Information

  • MACUGEN® (pegaptanib sodium injection) is contraindicated in patients with ocular or periocular infections, and in patients with known hypersensitivity to pegaptanib sodium or any other excipient in this product.
  • Intravitreous injections, including those with MACUGEN®, have been associated with endophthalmitis. Proper aseptic injection technique should always be utilized when administering MACUGEN®. In addition, patients should be monitored during the week following the injection to permit early treatment, should an infection occur.
  • Increases in intraocular pressure have been seen within 30 minutes of injection with MACUGEN®. Therefore, intraocular pressure as well as the perfusion of the optic nerve head should be monitored and managed appropriately.
  • Rare cases of anaphylaxis/anaphylactoid reactions, including angioedema, have been reported in post-marketing experience following the MACUGEN® intravitreal administration procedure.
  • Serious adverse events related to the injection procedure occurring in <1% of intravitreous injections included endophthalmitis, retinal detachment, and iatrogenic traumatic cataract.
  • Most common adverse reactions (reported in 10-40% of patients treated with MACUGEN® for up to two years) are anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, corneal edema, eye discharge, eye irritation, eye pain, hypertension, increased intraocular pressure (IOP), ocular discomfort, punctate keratitis, reduced visual acuity, visual disturbance, vitreous floaters, and vitreous opacities.

Click here for full Prescribing Information for MACUGEN®.

References: 1. MACUGEN [package insert], Bausch & Lomb Incorporated. 2. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.). Clinical Trial Group, Chakravarthy U, Adamis AP, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006 Sep;113(9):1508.e1-25. 3. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.). Clinical Trial Group, D'Amico DJ, Masonson HN, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology. 2006 Jun;113(6):992-1001.

Indication and Important Safety Information